TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Tivantinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms TIMES
- 09 Jun 2017 Planned End Date changed from 1 Oct 2019 to 1 Feb 2019.
- 09 Jun 2017 Status changed from recruiting to discontinued due to safety results.
- 20 Nov 2015 New trial record